热门资讯> 正文
Centessa Pharmaceuticals prices $250M offering at $21.5 per ADS
2025-11-12 16:22
- Clinical-stage pharmaceutical company Centessa Pharmaceuticals (CNTA) priced an underwritten public offering of ~11.63M ADSs, each representing one ordinary share, at a price to the public of $21.50 per ADS.
- The aggregate gross proceeds are expected to be ~$250M.
- All ADSs sold in the offering were offered by Centessa. The underwriters have a 30-day option to purchase up to an additional ~1.74M ADSs.
- The offering is expected to close on or about November 14, 2025
- The stock price fell 3.5% on Wednesday during pre-market hours of trading.
More on Centessa Pharmaceuticals
- Centessa rated Outperform at Oppenheimer on ORX750 potential
- Seeking Alpha’s Quant Rating on Centessa Pharmaceuticals
- Historical earnings data for Centessa Pharmaceuticals
- Financial information for Centessa Pharmaceuticals
推荐文章
港股周报 | 中国大模型“春节档”打响！智谱周涨超138%；巨亏超230亿！美团周内重挫超10%
一周财经日历 | 港美股迎“春节+总统日”双假期！万亿零售巨头沃尔玛将发财报
一周IPO | 赚钱效应持续火热！年内24只上市新股“0”破发；“图模融合第一股”海致科技首日飙涨逾242%
从软件到房地产，美国多板块陷入AI恐慌抛售潮
Meta计划为智能眼镜添加人脸识别技术
危机四伏，市场却似乎毫不在意
美股机会日报 | 降息预期升温！美国1月CPI年率创去年5月来新低；净利、指引双超预期！应用材料盘前涨超10%
财报前瞻 | 英伟达Q4财报放榜在即！高盛、瑞银预计将大超预期，两大关键催化将带来意外惊喜？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
